Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma

Holbrook E Kohrt, MD PhD, Jaqueline Chu, MD, Joshua Brody, MD, Debra K Czerwinski, Cariad Chester, Mohith Sadaram, BS, Ranjana Advani, MD, Youn H. Kim, MD, Richard T. Hoppe, MD, Susan J. Knox, MD PhD, Irene Wapnir, MD, Robert J. Tibshirani, PhD, Ron Levy, MD

Blood (2014) 124 (21): 3092.

https://doi.org/10.1182/blood.V124.21.3092.3092

Published: 2014

Journal Articles

Phase I, Multicenter, Open Label, Dose Escalation of 90 yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma

Christos Vaklavas, MD, Ruby F Meredith, M.D., Ph.D., Susan J. Knox, MD, PhD, Gregory Wiseman, MD, Thomas E. Witzig, MD, Ivana N. Micallef, MD, Albert F. Lobuglio, MD, Andres Forero, MD

Blood (2011) 118 (21): 1648.

https://doi.org/10.1182/blood.V118.21.1648.1648

Published: 2011

Journal Articles

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

Mark S. Kaminski, MD, Andrew D. Zelenetz, MD, Oliver W. Press, MD, PhD, Mansoor N. Saleh, MD, John P. Leonard, MD, Louis Fehrenbacher, MD, T. Andrew Lister, MD, Thierry J. Horner, PhD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Christina Vleisides, DC, Susan J. Knox, MD, PhD, Richard L. Wahl, MD, Julie M. Vose

Blood (2010) 116 (21): 3960.

https://doi.org/10.1182/blood.V116.21.3960.3960

Published: 2010

Journal Articles

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma

Youn H. Kim, Madeleine Duvic, Erik Obitz, Robert Gniadecki, Lars Iversen, Anders Österborg, Sean Whittaker, Timothy M. Illidge, Thomas Schwarz, Roland Kaufmann, Kevin Cooper, Kim M. Knudsen, Steen Lisby, Ole Baadsgaard, Susan J. Knox

Blood (2007) 109 (11): 4655–4662.

https://doi.org/10.1182/blood-2006-12-062877

Published: 2007

Journal Articles

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I 131 tositumomab

John M. Bennett, Mark S. Kaminski, John P. Leonard, Julie M. Vose, Andrew D. Zelenetz, Susan J. Knox, Sandra Horning, Oliver W. Press, John A. Radford, Stewart M. Kroll, Robert L. Capizzi

Blood (2005) 105 (12): 4576–4582.

https://doi.org/10.1182/blood-2004-12-4690

Published: 2005

Journal Articles

Tositumomab and Iodine I 131 Tositumomab (the BEXXAR® Therapeutic Regimen) Shows Efficacy in Elderly Patients (pts) with Relapsed/Refractory Low-Grade (LG), Follicular, and Transformed Non-Hodgkin’s Lymphoma (NHL).

Stephanie A. Gregory, Andrew Zelenetz, Susan J. Knox, Julie Vose, John P. Leonard, Mark Kaminski

Blood (2004) 104 (11): 2630.

https://doi.org/10.1182/blood.V104.11.2630.2630

Published: 2004

Journal Articles

Tositumomab and Iodine I 131 Tositumomab (The BEXXAR® Therapeutic Regimen) Produced Ongoing, Durable Remissions of More Than 5 Years in 9 Patients with Non-Hodgkin’s Lymphoma (NHL) in a Pivotal Study of Patients Refractory to Their Last Chemotherapy.

Mark S. Kaminski, MD, Andrew D. Zelenetz, MD, Oliver W. Press, MD, Mansoor N. Saleh, MD, John P. Leonard, MD, Louis Fehrenbacher, MD, T. Andrew Lister, MD, Stewart Kroll, PhD, Richard L. Wahl, MD, Susan J. Knox, MD, Julie M. Vose, MD.

Blood (2004) 104 (11): 2631.

https://doi.org/10.1182/blood.V104.11.2631.2631

Published: 2004

Journal Articles

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

Andres Forero, Paul L. Weiden, Julie M. Vose, Susan J. Knox, Albert F. LoBuglio, Jordan Hankins, Michael L. Goris, Vincent J. Picozzi, Don B. Axworthy, Hazel B. Breitz, Robert B. Sims, Richard G. Ghalie, Sui Shen, Ruby F. Meredith

Blood (2004) 104 (1): 227–236.

https://doi.org/10.1182/blood-2003-09-3284

Published: 2004

Journal Articles

A Prospective Study of Radiation Therapy-Associated Thrombocytopenia

Susan J. Knox, Anna Varghese, Waqqar Khan, Eric Chen, Michael MacManus, Gordon Ray, Karen Lee, Kathleen R. Lamborn

Blood (1997) 90 (10): 4237–4238.

https://doi.org/10.1182/blood.V90.10.4237

Published: 1997

NARROW

Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma

Phase I, Multicenter, Open Label, Dose Escalation of 90 yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I 131 tositumomab

Tositumomab and Iodine I 131 Tositumomab (the BEXXAR® Therapeutic Regimen) Shows Efficacy in Elderly Patients (pts) with Relapsed/Refractory Low-Grade (LG), Follicular, and Transformed Non-Hodgkin’s Lymphoma (NHL).

Tositumomab and Iodine I 131 Tositumomab (The BEXXAR® Therapeutic Regimen) Produced Ongoing, Durable Remissions of More Than 5 Years in 9 Patients with Non-Hodgkin’s Lymphoma (NHL) in a Pivotal Study of Patients Refractory to Their Last Chemotherapy.

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

A Prospective Study of Radiation Therapy-Associated Thrombocytopenia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only